The idea of a vaccine made just for you, designed to fight your specific cancer, sounds like science fiction. For Hyderabad-based biotech firm PopVax, it's a scientific reality in the making, though the road to approval is long.
What Are Personalised Cancer Vaccines?
Unlike traditional vaccines
that prevent infectious diseases, personalised cancer vaccines are therapeutic, meaning they are designed to treat cancer that already exists. The core idea is to create a 'wanted poster' for your immune system, showing it exactly what to hunt down and destroy. Every person's cancer has a unique genetic fingerprint, with specific mutations that don't exist in their healthy cells. These mutations can create unique markers on the surface of cancer cells, called neoantigens. A personalised vaccine is created by first taking a sample of a patient's tumour and sequencing its genetics to identify these neoantigens. An mRNA vaccine is then manufactured containing the instructions for these specific markers. When injected, the vaccine teaches the patient's own immune cells, particularly T-cells, to recognise and launch a precise attack against the cancer cells, leaving healthy tissue unharmed.
The Role of PopVax and its RNA Foundry
Hyderabad's PopVax, founded in late 2021, is at the forefront of this technology in India. The company has established an integrated facility called the RNA Foundry in collaboration with Stochastic Sciences. This facility brings research, development, and manufacturing of these complex RNA-based medicines under one roof. PopVax uses artificial intelligence and machine learning to analyse tumour genetics and predict which neoantigens will trigger the strongest immune response. This high-tech approach is crucial for designing each unique vaccine. The company has stated it aims to create over 100 personalised cancer vaccine candidates in the next year, with a potential turnaround of 8 to 10 weeks to create a vaccine for an individual patient. This work has attracted significant funding from global entities like the Bill & Melinda Gates Foundation, the US government's BARDA, and prominent tech investors.
Why Aren't They Approved Yet?
The journey from a promising concept to an approved medical treatment is long and filled with challenges. First, identifying the right neoantigens is incredibly complex. Tumours are often heterogeneous, meaning different cells within the same tumour can have different mutations. This makes choosing the right targets difficult. Second, even with the right targets, there is no guarantee the vaccine will provoke a strong enough immune response to eliminate the cancer, especially as tumours often create an 'immunosuppressive microenvironment' that actively fights back against immune cells. Finally, and most critically, every new treatment must undergo rigorous clinical trials to prove it is both safe and effective. PopVax's cancer vaccine candidates have not yet been administered to patients. While the company is also developing other vaccines—its COVID-19 candidate is already in a Phase I trial in Australia—that progress does not automatically apply to its separate cancer programme.
The Path Forward: Trials and Compassionate Use
While widespread approval is not on the immediate horizon, there are steps being taken. PopVax has indicated plans to initially work with a small number of doctors and patients outside India. This could happen through 'named-patient' and 'compassionate-use' pathways, which, subject to regulatory approvals, allow access to experimental treatments for patients with serious conditions who have exhausted other options. These early cases will provide crucial data to guide the design of larger, more formal clinical trials, which are essential to prove safety and efficacy. PopVax is focusing its efforts on hard-to-treat cancers with poor survival rates, such as liver and pancreatic cancer, where new treatment options are desperately needed. The vaccines are intended to be used alongside existing treatments, like immunotherapy drugs, to amplify the body's anti-cancer response.
